Fibromyalgia sits at the intersection of pain, sleep, mental health and overall quality of life. It's notoriously hard to treat. Conventional approaches give partial relief at best, and many people end up managing a tangle of symptoms without one treatment that addresses all of them. CST is something people in this situation often look at.
A randomised controlled trial of 84 fibromyalgia patients offered one of the more carefully designed tests of whether CST might help. The study ran over 25 weeks, comparing CST to a credible placebo — disconnected ultrasound, which looks and feels like treatment but delivers no active therapeutic effect. Results measured six months after treatment ended showed significant improvements in anxiety, depression and quality of life.
It's one of the more encouraging longer-term trials in CST research. Worth understanding what it found and how it was set up.
Why disconnected ultrasound works as a placebo
One of the persistent problems in CST research is creating a credible sham condition. Participants need to believe they might be receiving real treatment for the placebo to do its job. Otherwise the comparison group knows they're getting nothing, which confounds the results.
Disconnected ultrasound solves this neatly. The device is applied, switched on with lights and sounds, and the practitioner moves it over the relevant areas. But it delivers no actual ultrasound energy. From the participant's side it looks and feels like a treatment. The attention, the time in the room, the physical contact — all of it is matched between the CST and placebo groups.
Which means that any difference in outcomes between the two is down to whatever CST specifically does, on top of the general benefits of attention, touch and expectation. Finding significant effects under those conditions is a stronger result than finding effects against no treatment at all.
What the outcomes measured and found
The study used several well-validated assessment tools. The Fibromyalgia Impact Questionnaire (FIQ) measures the overall impact of the condition on daily functioning. The SF-36 is a broad quality-of-life measure covering physical and mental health. The Hospital Anxiety and Depression Scale (HAD) measures, as the name suggests, anxiety and depression — two experiences closely entwined with fibromyalgia for many patients.
At six months post-treatment, participants who had received CST showed significantly better scores on anxiety, depression and quality of life than those in the placebo group. Not small statistical effects in marginally powered analyses. Clinically meaningful differences on validated tools at a time point six months after the active treatment period had ended.
The durability is particularly notable. Many treatment effects in clinical trials fade quickly when the treatment ends. A result that persists at six months suggests something more lasting is happening — whether that's a real physiological change, a shift in the person's relationship to their symptoms, or something more complicated.
What this adds for fibromyalgia
This trial is one of the better-designed CST studies available, and its findings matter for people with fibromyalgia thinking about trying the therapy. The comparison group had a credible placebo. The sample size was reasonable. The follow-up was meaningful. Not the same as some of the weaker trials in the broader CST literature.
Fibromyalgia affects a person's whole life. Not only their pain scores, but sleep, relationships, ability to work and take part in things they care about. Treatments that move the pain dial slightly while leaving everything else unchanged don't feel helpful, even when they show some technical effect. Improvements in anxiety, depression and quality of life may matter more to many fibromyalgia patients than reductions in raw pain intensity.
This study doesn't prove CST works for fibromyalgia in some absolute scientific sense. One well-designed trial, however encouraging, needs replication before strong conclusions are warranted. But it does offer genuinely useful evidence that CST is worth considering for this population, and gives practitioners and clients a more concrete basis for that conversation.
The fibromyalgia RCT is among the strongest evidence for CST in any specific condition. Its credible placebo and six-month follow-up make it a particularly meaningful piece of the evidence landscape for people managing this complex condition.